

SUPPLEMENTARY TABLE S1. NEUROLOGICAL PROPERTIES OF THE PATIENTS ON STUDY ENTRY  
(THERE WERE NO SIGNIFICANT BETWEEN-GROUP DIFFERENCES)

	<i>Delayed-start group</i>	<i>Early-start group</i>	<i>p value</i>
Number of patients	19	21	
Age at study entry (years)	60 [54–64]	61 [54–66]	0.7
Gender ratio	6 F/13 M	9 F/12 M	—
Time since diagnosis (years)	2 [1–3]	2 [1–3]	0.9
Hoehn and Yahr stage (range, 1–5)	2 [1.5–2]	2 [1.5–2]	0.85
Daily L-dopa dose equivalent (mg)	300 [162–510]	300 [150–532]	0.87
Number of patients on L-dopa	9	10	—
Patients on dopaminergic agonists (mean mg daily L-dopa equivalent)	18 (243)	18 (220)	0.64
Number of patients with L-dopa and agonists	7	7	—
Number of patients on rasagiline	3	3	—
Mini mental scale examination score	29 [28–30]	28 [26–30]	0.58
Mattis dementia rating scale score	139 [138–141]	139 [134–143]	0.54
Epworth Sleepiness Scale score	9 [7–13]	9 [5–13]	0.81
Montgomery asberg depression rating scale	3 [2–4]	4 [2–5]	0.74
Cognition and behavior: MDS-UPDRS part I score	6 [5–8]	6 [4.7–9]	0.94

The dopaminergic drug treatments did not change over the course of the study.